Kolon TissueGene

Kolon TissueGene is a biopharmaceutical company located in Maryland that focuses on developing regenerative therapies for the treatment of various orthopedic conditions. The company’s core technology utilizes a cell therapy to deliver therapeutic proteins directly to the localized area of damaged tissue. The sustained expression of these proteins triggers rapid repair of the damaged tissue without the need for invasive surgery. TissueGene is currently developing four product candidates—TG-C, TG-B, TG-D, and TG-N—for the regeneration of cartilage, intervertebral discs, and nerves. The company’s lead product candidate, TG-C, is being developed for the treatment of knee osteoarthritis and is currently in Phase II clinical trials in the United States and Phase III clinical trials in South Korea.